Heart failure and kidney dysfunction can lead to complex clinical challenges.
Join @CircHF & leading researchers for the latest insights on cardiorenal syndrome, diagnosis, and treatment strategies.
📍Nov 8 | N137 |⏰ 8:00-9:15 AM CT
#ScientificSessions26
In a large, retrospective, contemporary HFrEF cohort initiated on GDMT, NT-proBNP offered much greater prognostic value than LVEF. @WilsonTangMD https://t.co/wHwvOlE73h
From the CABANA trial: Patients with #HFpEF benefited even more from #Afib ablation regarding:
🔸Death/CV 🏥
🔸AF recurrence
Despite the greater benefit for HFpEF pts, their risk of recurrence remained ⬆️ than in those w/out HFpEF
📎: https://t.co/wxPf72B60o #JACCHF
@CardioNerdsJC This is in contrast with many HF trials that have resulted in neutral results, in part because many factors (cardiac or extra-cardiac) may affect pVO2 in pts with HF.
@CardioNerdsJC This is one scenario that change in pVO2 is a good choice for primary endpoint because the key determinant of pVO2 in oHCM is the obstructive physiology that is being relieved by the intervention.
Great start with our fearless leader @BurkhoffMd kicking off exciting #THT2024 with 3 days of packed agenda and exciting discussions in #heartfailure innovations.
Niacin, the B vitamin that was previously used to improve lipid profile and reduce the risk of heart disease, promotes arterial inflammation and cardiovascular risk through its metabolites
https://t.co/ZZw51MgO0y
@NatureMedicine
The new #JACCHF issue is now out!
Hemodynamic gain index and peak rate pressure product can identify patients w/ #HFrEF at risk of poor clinical outcomes. This allows prognostication of #HeartFailure even when CPET is not available. https://t.co/HoRswDCAJe
#CHF@WilsonTangMD
The MF is thrilled to announce one of the 2023 Fellowship Grant recipients, Dr. Simon Vanhentenrijk, MD, Pharm D, of the Cleveland Clinic!
Read about his work below.
https://t.co/bJRgkUzYCF